Back to trial detailsIntake questionnaire
Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
Applying to UT Health Houston · Houston, Texas
Answer a few short questions to share with the research team.
0 of 3 answered